Mandeep R. Mehra

Sep 9, 2024 | onlinelibrary.wiley.com | Ameesh Isath |Mandeep R. Mehra

Invited Editorial The persistent poor prognosis in cardiogenic shock: Insights from recent trials Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: 1-year outcomes of the multicentre, randomized ECMO-CS trial Petr Ostadal, Richard Rokyta, Jiri Karasek, Andreas Kruger, Dagmar Vondrakova, Marek Janotka, Jan Naar, Jana Smalcova, Marketa Hubatova, Milan Hromadka, Stefan Volovar, Miroslava Seyfrydova, Ales Linhart, Jan Belohlavek, for the ECMO-CS Investigators, European...

Aug 21, 2024 | healio.com | Scott Buzby |Erik Swain |Mandeep R. Mehra

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA approved updated labeling to remove aspirin as part of routine care after implant of Abbott’s fully magnetically levitated LVAD. The approval was based on the positive results of the ARIES-HM3 trial.

Nov 27, 2023 | cfrjournal.com | Mandeep R. Mehra |Christian Inchaustegui |Dipti Itchhaporia |Demilade Adedinsewo

AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156). ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens.

Nov 11, 2023 | jamanetwork.com | Mandeep R. Mehra |Ivan Netuka |Columbia College |Jason Katz

Key PointsQuestion  Can aspirin be safely avoided as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device (LVAD), and can such an approach reduce residual risk of nonsurgical bleeding complications?

Nov 7, 2023 | cfrjournal.com | Harriette Van Spall |Mandeep R. Mehra |Giuseppe Rosano

AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial. ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens.